Print Page Print Page  |  RSS Feeds RSS Feeds  |  E-mail Alerts E-mail Alerts  |  IR Contacts IR Contacts  |  Financial Tear Sheet Financial Tear Sheet

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/13/18Delcath Announces Third Quarter Fiscal 2018 Financial Results
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30, 2018. Highlights from the third quarter of 2018 and recent weeks include: First patients treated in the Company’s amended Phase 3 clinical trial in ocular melanoma liver metastases (the FOCUS Trial) Raised $7.0 million in net proceeds from t... 
Printer Friendly Version
10/18/18Delcath Announces Enrollment of First Patient in ALIGN Trial
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydroch... 
Printer Friendly Version
10/15/18Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases. These centers join Stanford Medical Center in ini... 
Printer Friendly Version
10/15/18CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath Systems, Inc. (OTCQB: DCTH), please note the first sentence of the first paragraph should read: "Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancer centers of the liver, announces the addition of six major cancer centers in the Un... 
Printer Friendly Version
10/04/18Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
PHP Therapy in ICC Treatment Shows Promise in Retrospective Analysis NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of D... 
Printer Friendly Version
09/27/18Delcath Raises $8.1 Million from Shareholders in Rights Offering
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subscription period of its previously announced rights offering. The rights offering was made pursuant to a Registration Statement on Form S-1 that was made effective on August 3, 2018. At the end of the subscription period on September 26, 2018, Delcath had received 4,249,604 ba... 
Printer Friendly Version
09/26/18Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
Positive Results Observed in Study Endpoints Comparable to Endpoints in Delcath Registration Trial NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective study conducted by Leiden University Medical Center (LUMC) in The Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metas... 
Printer Friendly Version
09/24/18Data on Delcath’s PHP Therapy presented at CIRSE 2018
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, was presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. ... 
Printer Friendly Version
09/13/18Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be exercisable until 5:00 p.m. Eastern time on September 26, 2018, though most broker dealers will require holders of rights to exercise in advance of this date. Holders of rights should confirm deadlines with ... 
Printer Friendly Version
09/04/18Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been accepted for publication in the journal European Radiology. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in P... 
Printer Friendly Version
08/28/18Delcath Announces Extension of Rights Offering Period to September 26, 2018
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an additional 30-day period, until 5:00 PM Eastern time on September 26, 2018. About Delcath Systems Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver c... 
Printer Friendly Version
08/27/18Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIR... 
Printer Friendly Version
08/23/18Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 clinical trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data fo... 
Printer Friendly Version
08/22/18Delcath Announces Pending Expiration to Rights Offering Subscription Period
Reminder of August 27, 2018 Deadline NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday August 27, 2018, of the subscription period for its previously announced rights offering that began on Tuesday, August 7, 2018.  The Company also reminds holders of rights that most broker/dealers require clients to ... 
Printer Friendly Version
08/21/18First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to enroll a patient under the amended protocol. The trial, A Single-arm, Multi-Center, Open-Label Study t... 
Printer Friendly Version
08/20/18Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
Stanford University Medical Center First Location to Begin Enrollment Under Single Arm Protocol NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to obtain Institut... 
Printer Friendly Version
08/17/18Delcath Issues Letter to Stockholders
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the Company's website, is as follows. Dear Stockholders: Over the ... 
Printer Friendly Version
08/15/18Delcath Announces Second Quarter Fiscal 2018 Financial Results
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June 30, 2018. Highlights from the second quarter of 2018 and recent weeks include: Amendment of the Company’s ongoing Phase 3 clinical trial in ocular melanoma liver metastases to a non-randomized, single-arm trial Initiation of a $50 million rights offe... 
Printer Friendly Version
08/06/18 Delcath Announces Commencement of Rights Offering Subscription Period
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday, August 7, 2018 (upon declaration of effectiveness of its registration statement on Form S-1 by the SEC). Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights ... 
Printer Friendly Version
07/31/18Summary of Calendar for Upcoming Proposed Delcath Rights Offering
The Company's Directors and Officers Indicate Intent to Participate in the Rights Offering Once EffectiveNEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds investors that the ownership date cutoff for the Company's upcoming rights offering is August 1, 2018 at 4 P.M. Eastern Time.  The Company previously filed a registration statement with the ... 
Printer Friendly Version
07/27/18Delcath Amends Phase 3 Ocular Melanoma Trial Protocol
Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) --  Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has filed an amendment with the U.S. Food & Drug Administration to revise the protocol for its Phase 3 clinical trial in ocular me... 
Printer Friendly Version
07/16/18Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights offering for up to 28,571,429 shares of common stock at the subscription price of $1.75 per share. Under the terms of the rights offering, on August 3, 2018, Delcath expects to distribute, at no charge, 500 non-transfera... 
Printer Friendly Version
07/09/18Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by Dr. Mark C. Burgmans, completed their 100th treatment with PHP® Therapy using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). CHEMOSAT was launched in select European markets in 2012, and physicians the... 
Printer Friendly Version
05/29/18Delcath Systems to Present at the 8th Annual LD Micro Invitational
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors. Dr. Simpson’s presentation will be webcast... 
Printer Friendly Version
05/22/18Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event.  A Cure in Sight is a patient advocacy group dedicated to providing patient services for ocular melanoma patients and their families. Looking for a Cure was held in Palo Alto, CA at the Byers Eye Institute on May 20, 2018. ... 
Printer Friendly Version
05/16/18Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines, which represents the highest level within the classificati... 
Printer Friendly Version
05/14/18Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. M.C. Burgmans of Leiden University Medical Center (LUMC) in the Netherlands presented the training in the main auditorium session dedicat... 
Printer Friendly Version
05/10/18Delcath Announces First Quarter 2018 Financial Results
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March 31, 2018. Highlights from the first quarter of 2018 and recent weeks include: Revenue from European sales for the quarter was $0.7 million; Completed a $5.0 million capital raise in February 2018; Announced that the independent Data Safety Monitor... 
Printer Friendly Version
05/07/18Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
Duke Medical Center Opens for Patient Enrollment NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). Duke Medical Center in Durham, North Car... 
Printer Friendly Version
05/04/18Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York. Dr. Simpson’s presentation details are as follows: Panel Presentation: ... 
Printer Friendly Version
05/03/18Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial
FOCUS trial to continue without modification NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. The DSMB has again recommended that th... 
Printer Friendly Version
05/01/18Delcath Announces Ratio for Reverse Split Authorization
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1-for-500 (the Reverse Stock Split Authorization). The Company’s Board of Directors was authorized to effect the reverse split by shareholder approval of its Consent Solicitation filed with... 
Printer Friendly Version
04/09/18Delcath Announces Shareholder Approval of Consent Solicitation
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that shareholders have approved the provisions of the Company’s Consent Solicitation filed with the Securities Exchange Commission (SEC) on February, 26, 2018. By a vote of 54.3%, shareholders as of the record date of February 9, 2018 approved the Company’s proposals to amend its certificate of incorporat... 
Printer Friendly Version
04/03/18Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology  
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Dr. Brian Steadman, Interventional Oncologist at the Southampton University Hospital will present a video training session at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. Steadman will present an overview of the Percutaneous Hepatic Perfusion (PHP) procedure an... 
Printer Friendly Version
03/29/18Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that a comparative summary of recently published research on the Company’s PHP® Therapy was presented at the 2018 Society of Surgical Oncology Annual Cancer Symposium (SSO), held in Chicago, IL March 21-24, 2018. In a presentation entitled Percutaneous Hepatic Perfusion (PHP) in Hepatic Liver Metastase... 
Printer Friendly Version
03/19/18Delcath to Present at Oppenheimer 28th Annual Healthcare Conference
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday March 21, 2018 at 3:55pm Eastern Time. Dr. Simpson will highlight the recent corporate developments and provide an overview of the Com... 
Printer Friendly Version
03/16/18Delcath Announces 2017 Financial Results
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the twelve months ended December 31, 2017. Highlights from the fourth quarter of 2017 and recent weeks include: Revenue from European sales for 2017 increased 35% to $2.7 million from $2.0 million in 2016; Satisfaction of all obligations under the privately placed senior s... 
Printer Friendly Version
03/12/18Delcath to Present at 30th Annual Roth Conference
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will present at the Roth Capital Partners 30th Annual Conference on Tuesday March 13, 2018 at 1:30pm Pacific Time. Dr. Simpson will highlight the recent corporate developments and provide an overview of the Compan... 
Printer Friendly Version
03/07/18Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has entered into a commercial supply agreement with Tillomed Laboratories, an EMCURE company, for the procurement of melphalan for use with Delcath’s Hepatic CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.  Based in Luto... 
Printer Friendly Version
02/02/18Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP Therapy® treatment using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). CHEMOSAT was launched in select European markets in 2012, and physicians there have used it to treat a wide variety of cancers of the liver.   Jennifer K. Simpson, ... 
Printer Friendly Version
02/01/18Delcath Announces Satisfaction of 2016 Convertible Note
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016.  On December 28, 2017, Delcath entered into exchange agreements with  two institutional investors pursuant to which those investors were issued, in ex... 
Printer Friendly Version
01/10/18Delcath Announces Special Protocol Agreement Modification With FDA
NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has concluded a modification agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (The FOCUS Trial).... 
Printer Friendly Version
01/09/18Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath’s PHP® Therapy have been published in the peer-reviewed Journal of Surgical Oncology. The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by r... 
Printer Friendly Version